Translational Research in Oncology (TRIO) Initiates Phase I Study for MT-5111
Molecular Templates, Inc. (MTEM)
Last molecular templates, inc. earnings: 11/12 05:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.mtem.com/investor-relations
Company Research
Source: GlobeNewswire
EDMONTON, Alberta, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced enrolment of the first patient in a Phase I study with its partner Molecular Templates (Nasdaq: MTEM). This Phase I first-in-human study is an open-label, dose escalation and expansion study of MT-5111 given as monotherapy in subjects with HER2-positive solid tumors. The primary objective of the trial is to evaluate the safety and tolerability and determine the recommended Phase II dose of MT-5111 in subjects with advanced HER2-positive solid tumors. “We are excited to be working with Molecular Templates and their novel therapeutic for patients with previously treated advanced HER2-positive solid tumors,” says Launa Aspeslet, PhD, CEO of TRIO. “Given TRIO’s extensive experience in the HER2 space, as a direct result of the work by our Executive Director, Dr. Dennis Slamon, this study is the perfect fit for TRIO.
Show less
Read more
Impact Snapshot
Event Time:
MTEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MTEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MTEM alerts
High impacting Molecular Templates, Inc. news events
Weekly update
A roundup of the hottest topics
MTEM
News
- Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules [Yahoo! Finance]Yahoo! Finance
- Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing RulesGlobeNewswire
- Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price RequirementsGlobeNewswire
MTEM
Sec Filings
- 12/19/24 - Form 8-K
- 12/4/24 - Form DEFA14A
- 12/4/24 - Form 8-K
- MTEM's page on the SEC website